Results 231 to 240 of about 276,902 (250)

Biomarkers for severe eosinophilic asthma [PDF]

Journal of Allergy and Clinical Immunology, 2017
The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that ...
Frank Albers, Hector Ortega, Ian D. Pavord   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice

Journal of Personalized Medicine, 2022
Konstantinos Porpodis, Ioanna Tsiouprou, Kalliopi Domvri   +2 more
exaly  

Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma

Journal of Asthma, 2021
Barak Pertzov, Dorit Shitenberg, Osnat Shtraichman   +2 more
exaly  

Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study

Therapeutic Advances in Respiratory Disease, 2021
Giuseppe Spadaro, Aikaterini Detoraki, Remo Poto   +2 more
exaly  

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Chest, 2021
Brian D Kent, David J Jackson, Abdel Douiri   +2 more
exaly  

Eosinophilic Inflammation in Asthma

New England Journal of Medicine, 1990
Per Venge, Jean Bousquet, Pascal Chanez
exaly  

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

New England Journal of Medicine, 2014
Guy Brusselle, Alfredo Chetta, Hector Ortega   +2 more
exaly  

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Clinical Therapeutics, 2019
Robert G Price, Guy Brusselle, Frank Albers   +2 more
exaly  

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Lancet, The, 2012
Hector Ortega, Ian D. Pavord, Eugene R Bleecker   +2 more
exaly  

Non-eosinophilic cor ticosteroid unresponsive asthma

Lancet, The, 1999
Andrew Wardlaw, Ian D. Pavord, Chris Brightling   +2 more
exaly